ReNTox 100U

ReNTox 100U is a next-generation botulinum toxin type A formulation developed by PharmaResearchBio in Korea. Supplied as a lyophilized white powder in a clear, colorless vial, it is designed for precise and consistent aesthetic treatments.

Rapid onset and long duration
Patients may begin to notice visible effects as early as 3 days post-injection, with results typically lasting 6–8 months, depending on individual response and treatment area.

Refined composition
The formulation is engineered without added proteins, albumin, or gelatin, which may help reduce the risk of unnecessary antigenic exposure compared to some conventional botulinum toxin products.

Low diffusion profile
ReNTox is developed to exhibit minimal diffusion, supporting targeted action and helping practitioners achieve more controlled, localized outcomes.

Clinical Performance

ReNTox is manufactured under strict potency controls, with unit consistency maintained within a tightly regulated range (approximately 91–115 units). This standardization aims to ensure predictable dosing, uniform muscle relaxation at the injection site, and a high level of patient satisfaction in clinical aesthetic practice.